Timber pharmaceuticals discloses communication from nyse american

Warren, nj, july 03, 2023 (globe newswire) -- via newmediawire – timber pharmaceuticals, inc. ("timber" or the “company”) (nyse american: tmbr), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on june 28, 2023 it received a letter (the “notice”) from the nyse american llc (“nyse american” or the “exchange”) advising the company is not in compliance with the nyse american continued listing standards set forth in sections 1003(a)(i) and (ii) of the nyse american company guide given the reported stockholders' deficit as of march 31, 2023, and losses from continuing operations and/or net losses in its four most recent fiscal years then ended.
TMBR Ratings Summary
TMBR Quant Ranking